Company profile: Sonalasense
1.1 - Company Overview
Company description
- Provider of noninvasive sonodynamic therapy (SDT) that combines a proprietary intravenous ALA formulation (SONALA-001) with MR-guided focused ultrasound to induce necrosis and apoptosis in gliomas, including glioblastoma multiforme (GBM); conducts clinical trials in solid tumors and advances a pipeline to expand indications across multiple tumor types.
Products and services
- Sonodynamic Therapy (SDT): A noninvasive, MR-guided treatment combining SONALA-001 with focused ultrasound to induce necrosis and apoptosis in gliomas
- SONALA-001: A proprietary intravenous formulation of aminolevulinic acid (ALA) used with MR-guided focused ultrasound to power sonodynamic therapy in gliomas
- Clinical Trials for SDT: Company-conducted studies evaluating the efficacy and safety of sonodynamic therapy in treating various types of solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sonalasense
Ikonisys
HQ: United States
Website
- Description: Provider of fully automated microscopy platforms and FISH-based diagnostic applications for early, accurate, non-invasive disease detection, including Ikoniscope20 for rare-cell detection and Ikoniscope20max with high-volume slide loading, plus oncoFISH solutions for bladder cancer (urine), HER2 status, cervical 3q26 gain in LSIL/ASCUS, and ALK gene rearrangements in non-small cell lung carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikonisys company profile →
Carrick Therapeutics
HQ: Ireland
Website
- Description: Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carrick Therapeutics company profile →
AltruBio
HQ: United States
Website
- Description: Provider of targeted antibody therapeutics for cancer and immune related inflammatory diseases, including ALTB-168, a humanized antibody targeting late-stage, chronically activated T cells with clinical efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and acute graft versus host disease, and ALTB-268, a second-generation antibody in trials for ulcerative colitis and psoriatic arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltruBio company profile →
Fate Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fate Therapeutics company profile →
JW Holdings
HQ: South Korea
Website
- Description: Provider of prescription drugs, over-the-counter drugs, and medical equipment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JW Holdings company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sonalasense
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sonalasense
2.2 - Growth funds investing in similar companies to Sonalasense
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sonalasense
4.2 - Public trading comparable groups for Sonalasense
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →